Cargando…

C-erbB-2 overexpression in primary breast cancer: relationship to clinical and histopathological parameters of patients with breast cancer

Detalles Bibliográficos
Autores principales:	Regele, S, Vogel, FD, Runnebaum, IB, Kreienberg, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2001
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300561/ http://dx.doi.org/10.1186/bcr378

Ejemplares similares

Estrogen receptor transcription and transactivation: ErbB family of receptors in breast cancer
por: Hynes, NE, et al.
Publicado: (2001)

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
por: Stal, O, et al.
Publicado: (2000)

Pathway pathology: the wnt and erbB mammary tumors
por: Rosner, A, et al.
Publicado: (2001)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Structural basis for the oncogenic signalling complex formed by Grb2 and Gab2 in Her2 (ErbB2/Neu)-driven breast cancers and CML cells
por: Tsirka, T, et al.
Publicado: (2009)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice
por: Parris, Amanda B., et al.
Publicado: (2017)

Proteolytic Processing of ErbB4 in Breast Cancer
por: Hollmén, Maija, et al.
Publicado: (2012)

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Essential function for ErbB3 in breast cancer proliferation
por: Perez-Nadales, Elena, et al.
Publicado: (2004)

Treatment of ErbB2 breast cancer by mitochondrial targeting
por: Eldad, Sophia, et al.
Publicado: (2020)

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
por: Houston, S J, et al.
Publicado: (1999)

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins
por: Hutcheson, IR, et al.
Publicado: (2010)

Effect of anthracyclin-based neoadjuvant chemotherapy on disseminated tumor cells in breast cancer patients: an immunocytologic and molecular approach
por: Jäger, CM, et al.
Publicado: (2001)

Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast
por: Regele, S, et al.
Publicado: (1999)

Cyanidin-3-Glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2
por: Xu, Mei, et al.
Publicado: (2010)

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.
por: O'Reilly, S. M., et al.
Publicado: (1991)

c-erbB-4 protein expression in human breast cancer
por: Kew, T Y, et al.
Publicado: (2000)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Activation of the Her2/neu receptor leads to antiestrogen resistance, but acquired resistance is not caused by altered ErbB expression and activation
por: Larsen, SS, et al.
Publicado: (2000)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
por: Wang, Lingfei, et al.
Publicado: (2017)

Critical determination of the frequency of c-erbB-2 amplification in breast cancer.
por: Hubbard, A. L., et al.
Publicado: (1994)

c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
por: Lovekin, C., et al.
Publicado: (1991)

c-erbB-2 oncogene as a prognostic marker in breast cancer.
por: Perren, T. J.
Publicado: (1991)

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer
por: Foster, Fiona M, et al.
Publicado: (2009)

Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.
por: Mehta, R. R., et al.
Publicado: (1995)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
por: Vogel, Charles, et al.
Publicado: (2010)

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.
por: Gullick, W. J., et al.
Publicado: (1991)

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
por: Hutcheson, Iain R, et al.
Publicado: (2011)

Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2019)

Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2/COX2/MDR1 axis
por: Liu, Yun, et al.
Publicado: (2023)

The long term prognostic significance of c-erbB-2 in primary breast cancer.
por: Winstanley, J., et al.
Publicado: (1991)

Prognostic significance of c-erbB-2 expression in node negative breast cancer.
por: Bianchi, S., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_bho74nfjjac2fq7aop8aa9ilbm